Guardant Health, Inc.
A precision-oncology company that spots cancer with simple blood tests, including the Shield test, the first FDA-approved blood test for colorectal cancer screening, plus the Guardant360 CDx for guiding treatment and Guardant Reveal for watching for recurrence. Co-founded in 2012 by two Stanford PhDs, Helmy Eltoukhy and AmirAli Talasaz, it was built on the idea of catching cancer's genetic "signature" floating in the bloodstream. Its Shield test was designed to make cancer screening as easy as a routine blood draw, avoiding the preparation many people dread.
Granted 964.9K · Bought 201.5K · Sold 997.5K
Granted 626.2K · Bought 197.6K · Sold 490.6K
Granted 177.8K · Sold 28.4K
Granted 130.7K
Granted 166.6K · Sold 55.9K
Granted 203.3K · Sold 85.4K
Granted 176.1K · Bought 5.8K · Sold 87.7K
Granted 127.1K · Sold 39.0K
Granted 23.8K
Granted 15.1K · Sold 9.0K
Granted 135.7K · Sold 77.6K
Granted 25.3K · Sold 4.3K
Granted 7.3K
Granted 35.2K · Sold 19.8K
Granted 23.7K · Sold 9.3K
Granted 20.6K · Sold 9.6K
Granted 9.7K
Granted 59.6K · Sold 51.6K
Granted 1.8K
Granted 36.4K · Sold 34.5K
Granted 13.5K · Sold 8.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Talasaz AmirAliCo-Chief Executive Officer, Director · 106 transactions | — | 6.65M | 964.9K | 201.5K | 997.5K |
| Eltoukhy HelmyCo-Chief Executive Officer, Director · 70 transactions | — | 6.16M | 626.2K | 197.6K | 490.6K |
| Chudova DaryaChief Technology Officer · 85 transactions | — | 160.2K | 177.8K | — | 28.4K |
| Eagle CraigChief Medical Officer · 62 transactions | — | 72.4K | 130.7K | — | — |
| Freeman ChrisChief Commercial Officer · 75 transactions | — | 61.7K | 166.6K | — | 55.9K |
| Bell Michael BrianChief Financial Officer · 85 transactions | — | 48.5K | 203.3K | — | 85.4K |
| Kalia KumudChief Information Officer · 117 transactions | — | 41.4K | 176.1K | 5.8K | 87.7K |
| Saia John G.Chief Legal Officer · 102 transactions | +149.4% | 37.0K | 127.1K | — | 39.0K |
| Gadde VijayaDirector · 5 transactions | +506.4% | 28.5K | 23.8K | — | — |
| Merrill AmeliaSVP, People · 33 transactions | — | 27.5Kas of Mar 2024 | 15.1K | — | 9.0K |
| Monroe Terilyn J.Chief People Officer · 30 transactions | — | 21.0K | 135.7K | — | 77.6K |
| Potter Myrtle SDirector · 48 transactions | — | 21.0K | 25.3K | — | 4.3K |
| Kaul SamirDirector · 2 transactions | +81.6% | 16.3Kas of Jun 2023 | 7.3K | — | — |
| Joyce Meghan V.Director · 58 transactions | — | 15.4K | 35.2K | — | 19.8K |
| Krognes Steve E.Director · 40 transactions | — | 14.4K | 23.7K | — | 9.3K |
| Tariq MusaDirector · 49 transactions | — | 11.0K | 20.6K | — | 9.6K |
| Mignone RobertoDirector · 11 transactions | — | 10.0K | 9.7K | — | — |
| Clark Ian TDirector · 20 transactions | — | 8.1K | 59.6K | — | 51.6K |
| Jallal BahijaDirector · 1 transaction | +32.4% | 7.4Kas of Jun 2022 | 1.8K | — | — |
| Meresman Stanley JDirector · 17 transactions | -34.7% | 5.9Kas of Jun 2022 | 36.4K | — | 34.5K |
| Hidalgo Medina ManuelDirector · 27 transactions | — | 5.1K | 13.5K | — | 8.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.60M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.